<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006713</article-id><article-id pub-id-type="pmc">PMC11861575</article-id><article-id pub-id-type="doi">10.3390/vaccines13020166</article-id><article-id pub-id-type="publisher-id">vaccines-13-00166</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Effectiveness of Heterologous and Homologous Ad26.COV2.S Vaccine Boosting in Preventing COVID-19-Related Outcomes Among Individuals with a Completed Primary Vaccination Series in the United States</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nyaku</surname><given-names>Mawuli</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-vaccines-13-00166" ref-type="aff">1</xref><xref rid="c1-vaccines-13-00166" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Yoon</surname><given-names>Lara S.</given-names></name><xref rid="af2-vaccines-13-00166" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Ricci</surname><given-names>Deborah</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vaccines-13-00166" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Rubens</surname><given-names>Lexie</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af2-vaccines-13-00166" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Sheridan</surname><given-names>Paige</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af2-vaccines-13-00166" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Iyer</surname><given-names>Monica</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af2-vaccines-13-00166" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhen</surname><given-names>Thomas</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af2-vaccines-13-00166" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6795-519X</contrib-id><name><surname>Harvey</surname><given-names>Raymond A.</given-names></name><xref rid="af1-vaccines-13-00166" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Madsen</surname><given-names>Ann</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-vaccines-13-00166" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Tripp</surname><given-names>Ralph A.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-13-00166"><label>1</label>Johnson &#x00026; Johnson Innovative Medicine, Data Science and Digital Health, Spring House, PA 19002, USA; <email>dricci@its.jnj.com</email> (D.R.); <email>rharvey2@its.jnj.com</email> (R.A.H.)</aff><aff id="af2-vaccines-13-00166"><label>2</label>Aetion Inc., New York, NY 10001, USA<email>ann.madsen@aetion.com</email> (A.M.)</aff><author-notes><corresp id="c1-vaccines-13-00166"><label>*</label>Correspondence: <email>mnyaku@its.jnj.com</email></corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>166</elocation-id><history><date date-type="received"><day>03</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>05</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>07</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background/Objectives:</bold> COVID-19 vaccines have significantly reduced the mortality and morbidity associated with SARS-CoV-2. In the fall of 2021, the U.S. Food and Drug Administration amended its emergency use authorization guidelines for COVID-19 vaccines to allow the administration of booster vaccine doses based on sound scientific evidence of the increase in effectiveness conferred by boosters. The effectiveness of the Ad26.COV2.S COVID-19 booster vaccine during the periods of Delta and Omicron variant dominance is unknown. This study used real-world data to estimate the effectiveness of booster heterologous or homologous Ad26.COV2.S vaccination compared to that of a primary Ad26.COV2.S or mRNA COVID-19 vaccination series. <bold>Methods:</bold> A retrospective, observational, longitudinal cohort study design was used with a total eligible sample population consisting of 72,461,026 individuals in the HealthVerity dataset. The study cohort consisted of individuals &#x02265;18 years in the United States with evidence of a COVID-19 primary vaccination series (Ad26.COV2.S or mRNA) administered between 1 January 2021 and 6 July 2022. Two exposure groups were considered based on retrospective database classification: a heterologous Ad26.COV2.S booster and a homologous Ad26.COV2.S booster. Individuals eligible for the referent groups, defined as those with a primary vaccine series alone, were identified through exact matching by age, sex, time since primary series vaccine, location, and Gagne comorbidity score. Propensity score-matched Cox proportional hazards models were used to evaluate outcomes, including COVID-19-related hospitalization and medically attended COVID-19. <bold>Results:</bold> Depending on the comparison group of interest, the adjusted hazard ratios for COVID-19-related hospitalization ranged from 0.63 (95% CI: 0.56, 0.72) to 0.82 (95% CI: 0.75, 0.90), and 0.93 (95% CI: 0.90, 0.96) to 0.94 (95% CI: 0.91, 0.97) for medically attended COVID-19, both favoring booster vaccination. <bold>Conclusions:</bold> The results of this study demonstrate the effectiveness of an Ad26.COV2.S booster vaccination compared to primary series vaccination in preventing COVID-19 hospitalization and medically attended COVID-19 for at least 12 months. This study adds to the scientific evidence that demonstrates the importance of COVID-19 booster vaccinations to support public health policy.</p></abstract><kwd-group><kwd>COVID-19</kwd><kwd>adenovirus vaccine</kwd><kwd>booster vaccine</kwd><kwd>real-world data</kwd><kwd>real-world evidence</kwd></kwd-group><funding-group><award-group><funding-source>Johnson &#x00026; Johnson Innovative Medicine</funding-source></award-group><funding-statement>This work was funded by Johnson &#x00026; Johnson Innovative Medicine.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00166"><title>1. Introduction</title><p>The development and distribution of effective vaccines in the general population was proven to be a successful strategy for reducing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and the burden of coronavirus disease 2019 (COVID-19) [<xref rid="B1-vaccines-13-00166" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-13-00166" ref-type="bibr">2</xref>]. The Ad26.COV2.S COVID-19 vaccine, a one-dose adenovirus primary vaccination (Johnson &#x00026; Johnson Innovative Medicine), was given emergency use authorization (EUA) for adults aged 18+ by the Food and Drug Administration (FDA) on 27 February 2021 [<xref rid="B3-vaccines-13-00166" ref-type="bibr">3</xref>]. Despite the uptake rate of COVID-19 vaccines (of any type) reaching greater than 50% by May 2021 [<xref rid="B4-vaccines-13-00166" ref-type="bibr">4</xref>], the emergence of more transmissible SARS-CoV-2 variants (Delta and Omicron) in the summer and early fall months led to an increase in breakthrough infections among vaccinated persons and an observed waning vaccine effectiveness [<xref rid="B5-vaccines-13-00166" ref-type="bibr">5</xref>].</p><p>In September and October of 2021, the FDA amended the EUAs for the three COVID-19 vaccines, including Ad26.COV2.S, to allow a one-dose booster vaccination (from any manufacturer) at least 2 months after the completion of the Ad26.COV2.S primary regimen or at least 6 months after the completion of a two-dose mRNA primary series for eligible individuals [<xref rid="B6-vaccines-13-00166" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-13-00166" ref-type="bibr">7</xref>]. The FDA also authorized the use of heterologous booster doses, allowing for &#x0201c;mix-and-match&#x0201d; primary and booster COVID-19 vaccine regimens [<xref rid="B8-vaccines-13-00166" ref-type="bibr">8</xref>]. In preclinical and phase 2 studies, vaccine booster doses demonstrated an increase in binding and neutralizing antibodies, which are thought to increase protection against infection and severe illness [<xref rid="B9-vaccines-13-00166" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-13-00166" ref-type="bibr">10</xref>]. FDA decision-making was based on data from clinical trials that demonstrated the efficacy of a homologous Ad26.COV2.S booster dose when administered 2 months after the primary vaccination and a heterologous booster dose when administered 3 months after a primary series [<xref rid="B11-vaccines-13-00166" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-13-00166" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-13-00166" ref-type="bibr">13</xref>].</p><p>Several studies, including a recent meta-analysis, have assessed the longer-term effectiveness of booster vaccinations [<xref rid="B14-vaccines-13-00166" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-13-00166" ref-type="bibr">15</xref>]. However, evaluations of the Ad26.COV2.S COVID-19 vaccine in these studies were limited by small sample sizes, focusing on mRNA booster vaccinations or comparisons between boosted groups and unvaccinated groups. Few observational studies have reported on the effectiveness of the Ad26.COV2.S booster vaccination in heterologous and homologous combinations during the periods of Delta and Omicron variant dominance [<xref rid="B16-vaccines-13-00166" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-13-00166" ref-type="bibr">17</xref>]. Both studies only included hospitalized individuals and thus do not capture the entire spectrum of individuals who have received COVID-19 booster vaccines. Evidence on the real-world relative effectiveness of homologous and heterologous Ad26.COV2.S booster vaccines over periods of high-transmissibility variants is needed to inform evolving COVID-19 public health policy globally.</p><p>Here, we report results on the effectiveness of a booster heterologous or homologous Ad26.COV2.S vaccination compared to that of a primary Ad26.COV2.S or mRNA COVID-19 vaccination series in preventing COVID-19-related hospitalization and medically attended COVID-19 using real-world data.</p></sec><sec id="sec2-vaccines-13-00166"><title>2. Materials and Methods</title><p>This was a retrospective, observational, longitudinal cohort study of the real-world effectiveness of an Ad26.COV2.S booster vaccination in preventing COVID-19-related hospitalization and medically attended COVID-19.</p><sec id="sec2dot1-vaccines-13-00166"><title>2.1. Data</title><p>The study sample was identified from the HealthVerity Marketplace, a unified database of open and closed medical and pharmacy claims, hospital transactional records for inpatient and outpatient hospital encounters, and laboratory data for individuals in the U.S. The data encompass all major payer types (commercial, Medicaid, and Medicare), and they include details on service dates, medications, diagnoses, procedures, and laboratory testing activity (including COVID-19 diagnostic and antibody tests and results). Data elements in the dataset include both open and closed claims. The HealthVerity data are nationally representative of the U.S. population across age groups and most regions, with data coverage comparable to that reported by the 2010 Census Bureau&#x02019;s American Community Survey [<xref rid="B18-vaccines-13-00166" ref-type="bibr">18</xref>].</p></sec><sec id="sec2dot2-vaccines-13-00166"><title>2.2. Population and Exposure</title><p>Adults aged 18 years or older with evidence of a COVID-19 primary series vaccination (two mRNA vaccinations from the same manufacturer [Pfizer-BioNTech or Moderna] or one Ad26.COV2.S vaccination) administered between 1 January 2021 and 6 July 2022 and with at least 365 days of medical and pharmacy pre-index enrollment were eligible for the study cohorts (<xref rid="vaccines-13-00166-f001" ref-type="fig">Figure 1</xref>). The national drug codes (NDCs) or Current Procedural Terminology (CPT) codes used to identify the vaccines are provided in <xref rid="app1-vaccines-13-00166" ref-type="app">Supplemental Table S1</xref>. We considered two definitions of exposure or receipt of booster vaccination: a heterologous Ad26.COV2.S booster, defined as an Ad26.COV2.S booster administered at least 152 days after the completion of a two-dose mRNA primary series, and a homologous Ad26.COV2.S booster, defined as an Ad26.COV2.S booster administered at least 61 days after a one-dose Ad26.COV2.S primary vaccination [<xref rid="B19-vaccines-13-00166" ref-type="bibr">19</xref>]. We used 152 days because, at the time of protocol development and submission for IRB approval, the official FDA guidance of at least 6 months after the completion of a two-dose mRNA primary series for eligible individuals had not yet been developed. This 152-day period reflected the most scientifically accurate timeframe based on evolving data from clinical trials and scientific manuscripts in development. We compared groups of individuals with each exposure definition to those with an mRNA primary vaccine series (two doses) alone (i.e., without evidence of a booster vaccine) and to an Ad26.COV2.S vaccine (one dose) alone, for a total of four contrasts of interest (<xref rid="vaccines-13-00166-t001" ref-type="table">Table 1</xref>).</p><p>Separate analytic cohorts were identified for each contrast of interest using a combination of exact matching and propensity score (PS) matching. For each analytic cohort, individuals who received an Ad26.COV2.S booster vaccine (exposed group) were matched on the same calendar day with up to 10 referent individuals who had no evidence of a COVID-19 booster vaccination (referent group). Referent group individuals were matched by age (&#x000b1;5 years), sex, days since completed primary vaccination (&#x000b1;30 days), geographic location of residence (state) at index, and the Gagne combined comorbidity index (assessed over the 365-day baseline period) [<xref rid="B20-vaccines-13-00166" ref-type="bibr">20</xref>]. Exact matching was conducted without replacement.</p><p>After exact matching, exposed patients were then matched with up to four referent patients using parallel propensity score (PS) matching with a 1% caliper based on demographic and clinical characteristics in the baseline period in order to control for potential confounders. The PS model included the following characteristics: age, sex, Gagne comorbidity index score, calendar month of index date, calendar month of primary vaccination, state, insurance type, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, HIV infection status as defined by ICD-10-CM codes, immunocompromised status including from blood or organ transplant, liver disease, malignancies excluding non-melanoma skin cancer, moderate-to-severe asthma, cerebrovascular disease, chronic kidney disease, hypertension, serious heart condition, obesity, sickle cell disease, thalassemia, type 1 diabetes, type 2 diabetes, neurologic condition, COVID-19 history, recent (&#x02264;60 days from index) medical claims, and recent pharmacy claims. To assess the balance of measured confounders after PS matching, the absolute standardized difference (ASD) between the exposed and referent groups was examined; any measured covariates with a value &#x0003c;0.1 were considered balanced.</p></sec><sec id="sec2dot3-vaccines-13-00166"><title>2.3. Follow-Up and Outcomes</title><p>COVID-19-related hospitalization and medically attended COVID-19 were assessed as study outcomes. COVID-19-related hospitalization was defined as any inpatient medical claim or inpatient hospital encounter where any medically attended COVID-19 began in the 21 days prior to the start of the hospitalization and lasted until the final day of hospitalization. Medically attended COVID-19 was defined as a positive COVID-19 diagnostic test (NAAT) or any medical claim, inpatient hospital encounter, or outpatient hospital encounter indicating a diagnosis of COVID-19 (ICD-10-CM code: U07.1). Follow-up began 14 days after the index date and ended at the receipt of any additional COVID-19 vaccine after index, death, loss to follow-up/disenrollment from the insurance plan, the end of the study period (19 October 2022), or the occurrence of the outcome of interest during the follow-up period.</p></sec><sec id="sec2dot4-vaccines-13-00166"><title>2.4. Participant Characteristics</title><p>We evaluated the participant characteristics used in the PS matching over a 365-day baseline period using descriptive statistics. Additional baseline patient characteristics included the receipt of a COVID-19 laboratory test, the days since the primary COVID-19 vaccine series, and the number of medical and pharmacy claims. ASDs were reported for differences in characteristics between the exposed and referent groups, both pre- and post-PS matching. Demographic, clinical, and HCRU-related characteristics were described over the baseline period using summary statistics: for binary and categorical variables, counts and percentages (<italic toggle="yes">n</italic>, %) were used; for continuous variables, mean, standard deviation (SD), median, and interquartile range (IQR) were used.</p></sec><sec id="sec2dot5-vaccines-13-00166"><title>2.5. Statistical Analysis</title><p>Incidence rates per 1000 person-years and 95% confidence intervals (CIs) were calculated for each exposure and referent group. Cox proportional hazard models were used to report hazard ratios (HRs) and 95% CIs for the relative risk of study outcomes [<xref rid="B21-vaccines-13-00166" ref-type="bibr">21</xref>]. Doubly robust outcome models were used in cases where patient characteristics remained imbalanced after PS matching [<xref rid="B22-vaccines-13-00166" ref-type="bibr">22</xref>]. The proportional hazards assumption was assessed through a visual inspection of Kaplan&#x02013;Meier curves. Sensitivity analyses were conducted among individuals from the California state registry to assess the impact of potential vaccine underreporting.</p><p>To understand the potential effect of misclassification, we conducted sensitivity analyses in a subgroup of individuals residing in California using comprehensive COVID-19 vaccination data from the California state registry, linked to HealthVerity data (the results are not reported; see <xref rid="app1-vaccines-13-00166" ref-type="app">Supplementary Materials</xref>). No substantial differences in the results were noted between the primary analyses and the sensitivity analyses.</p></sec></sec><sec sec-type="results" id="sec3-vaccines-13-00166"><title>3. Results</title><p>Of the 548,788,380 individuals in the HealthVerity dataset as of 25 August 2023, 72,461,026 had evidence of a completed primary COVID-19 vaccination between 1 January 2021 and 6 July 2022. Approximately 90% (n = 65,000,652) had an mRNA primary vaccination between 1 January 2021 and 18 March 2022 (mRNA primary vaccine eligibility period), and 10% (n = 7,158,010) had an Ad26.COV2.S primary vaccination between 1 January 2021 and 6 July 2022 (Ad26.COV2.S primary vaccine eligibility period) (<xref rid="app1-vaccines-13-00166" ref-type="app">Supplemental Figures S1&#x02013;S4</xref>).</p><sec id="sec3dot1-vaccines-13-00166"><title>3.1. Descriptive Statistics</title><sec id="sec3dot1dot1-vaccines-13-00166"><title>3.1.1. Contrast: mRNA + Ad26.COV2.S vs. mRNA + No Boost</title><p>After meeting the eligibility criteria, exact matching, and PS matching, the final analytic cohort consisted of 2969 exposed patients (mRNA + Ad26.COV2.S) and 11,492 referent patients (mRNA + no boost) (<xref rid="vaccines-13-00166-t002" ref-type="table">Table 2</xref>). Of the 50 characteristics used for PS matching, two were unbalanced pre-PS matching (<xref rid="app1-vaccines-13-00166" ref-type="app">Supplemental Table S2a</xref>). After PS matching, all characteristics were balanced (<xref rid="vaccines-13-00166-t002" ref-type="table">Table 2</xref>). In the PS-matched cohort, the mean age was 47 years in both the exposed and referent groups. In both groups, the majority were male (53.3%, exposed; 54.5%, referent), located in the west (51.4%, exposed; 51.6%, referent), and had commercial insurance (54.9%, exposed; 55.2%, referent). A plurality of patients completed their primary vaccination series in April 2021 (34.8%, both groups) and received their booster vaccine in December 2021 (39.4%, exposed; 39.2%, referent). The most common comorbidities were hypertension, neurologic conditions, and obesity. Less than 10% of the patients had a history of COVID-19 infection.</p></sec><sec id="sec3dot1dot2-vaccines-13-00166"><title>3.1.2. Contrast: mRNA + Ad26.COV2.S vs. Ad26.COV2.S + No Boost</title><p>After meeting the eligibility criteria, exact matching, and PS matching, the final analytic cohort consisted of a total of 2973 exposed patients (mRNA + Ad26.COV2.S) and 11,568 referent patients (Ad26.COV2.S + no boost) (<xref rid="vaccines-13-00166-t002" ref-type="table">Table 2</xref>). Prior to PS matching, all characteristics were balanced (<xref rid="app1-vaccines-13-00166" ref-type="app">Supplemental Table S2a</xref>). In the PS-matched cohort, the mean age was 47 years, and the majority of patients were male (<xref rid="vaccines-13-00166-t002" ref-type="table">Table 2</xref>). More than half of each group was located in the west, had commercial insurance, and received their primary vaccine in April or May 2021. The most common comorbidities were hypertension, neurologic conditions, and obesity.</p></sec><sec id="sec3dot1dot3-vaccines-13-00166"><title>3.1.3. Contrast: Ad26.COV2.S + Ad26.COV2.S vs. mRNA + No Boost</title><p>After meeting the eligibility criteria, exact matching, and PS matching, the final analytic cohort consisted of 74,628 exposed patients (Ad26.COV2.S + Ad26.COV2.S) and 289,215 referent patients (mRNA + no boost) (<xref rid="vaccines-13-00166-t003" ref-type="table">Table 3</xref>). Of the 50 characteristics used for PS matching, one characteristic (month of primary vaccination: February 2021) was unbalanced pre-PS matching, and all characteristics were balanced post-PS matching (<xref rid="app1-vaccines-13-00166" ref-type="app">Supplemental Table S2b</xref>). Modest differences in demographic characteristics were observed in the contrasts evaluating a homologous Ad26.COV2.S booster vaccine against the heterologous Ad26.COV2.S booster vaccine. After PS matching, the mean age was 51 years in both the exposed and referent groups. Half of the cohort was male (49.5% male in both groups). The majority of the patients were located in the western U.S. (43.4% exposed; 44.1% referent) and had commercial insurance (51.8% exposed; 52.3%). Similarly to the previous comparisons, the majority of the patients completed their primary vaccination series in April 2021 (39.7% exposed; 40.2% referent) and their booster vaccine in November 2021 (34.8% exposed and referent). The most prevalent comorbidities were hypertension, neurologic conditions, and obesity.</p></sec><sec id="sec3dot1dot4-vaccines-13-00166"><title>3.1.4. Contrast: Ad26.COV2.S + Ad26.COV2.S vs. Ad26.COV2.S + No Boost</title><p>After meeting the eligibility criteria, exact matching, and PS matching, a total of 43,072 exposed patients (Ad26.COV2.S + Ad26.COV2.S) and 166,907 referent patients (Ad26.COV2.S + no boost) were included in the analytic cohort. Two characteristics (recent medical claim and recent pharmacy claim) were unbalanced pre-PS matching (<xref rid="app1-vaccines-13-00166" ref-type="app">Supplemental Table S2b</xref>); all characteristics were balanced after PS matching (<xref rid="vaccines-13-00166-t003" ref-type="table">Table 3</xref>). After PS matching, the mean age was 49 years in both the exposed and referent groups. Half of the cohort was male; additionally, the cohort was predominantly located in the western U.S., and the majority had commercial insurance. The majority of the patients completed their primary vaccination series in April 2021 and their booster vaccine in November 2021. The most prevalent comorbidities were hypertension, neurologic conditions, and obesity.</p></sec></sec><sec id="sec3dot2-vaccines-13-00166"><title>3.2. Main Results</title><p>The incidence rate of COVID-19-related hospitalization was 12.3 hospitalizations per 1000 PY among those with an mRNA + Ad26.COV2.S exposure, compared to 18.9 hospitalizations per 1000 PY among those with an mRNA vaccine with no booster (<xref rid="vaccines-13-00166-t004" ref-type="table">Table 4</xref>). The adjusted HR for COVID-19-related hospitalization was 0.67 (95% CI: 0.43, 1.06). Similarly, the medically attended COVID-19 incidence rates for the exposed and referent groups were 138.2 cases and 170.7 cases per 1000 PY, respectively, resulting in an HR of 0.84 (95% CI: 0.73, 0.97).</p><p>The incidence rate of COVID-19-related hospitalization was 12.3 cases per 1000 PY among those with an mRNA + Ad26.COV2.S exposure, compared to 15.7 cases per 1000 PY among those with an Ad26.COV2.S vaccine with no booster (HR 0.81, 95% CI: 0.51, 1.27, <xref rid="vaccines-13-00166-t004" ref-type="table">Table 4</xref>). The HR of medically attended COVID-19 was 0.88 (95% CI: 0.76, 1.01).</p><p>Among those in the Ad26.COV2.S + Ad26.COV2.S exposure group, the incidence rate of COVID-19-related hospitalization was 10.6 per 1000 PY; in the mRNA + no boost referent group, the incidence rate was 13.9 per 1000 PY (<xref rid="vaccines-13-00166-t004" ref-type="table">Table 4</xref>), resulting in an HR of 0.82 (95% CI: 0.75, 0.90). A similarly higher rate of events was observed for medically attended COVID-19. The HR of medically attended COVID-19 was 0.93 (95% CI: 0.90, 0.96).</p><p>The risk of COVID-19-related hospitalization was lower among those with an Ad26.COV2.S + Ad26.COV2.S exposure than among those with an Ad26.COV2.S vaccine with no booster (HR 0.63, 95% CI: 0.56, 0.72). The HR of medically attended COVID-19 was 0.94 (95% CI: 0.91, 0.97).</p><p>We observed similar incidence rates and hazard ratios across all four contrasts of interest when limiting the study cohort to those in the California state registry (<xref rid="app1-vaccines-13-00166" ref-type="app">Supplemental Table S5</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-13-00166"><title>4. Discussion</title><p>To the best of our knowledge, this is the largest study to date evaluating the real-world comparative effectiveness of heterologous and homologous booster vaccinations with Ad26.COV2.S for the prevention of COVID-19-related outcomes in the 12 months following the FDA emergency use authorization of a booster dose among a sample of U.S. individuals with a completed COVID-19 primary vaccination. Overall, the findings of this analysis demonstrate that booster vaccinations are effective in preventing COVID-19-related outcomes. The results of this study demonstrate the public health importance of boosting to prevent serious COVID-19 outcomes, including COVID-19-related hospitalization and medically attended COVID-19.</p><p>Although the Ad26.COV2.S EUA has recently expired and the vaccine is no longer available in the U.S., the findings of this study contribute to an understanding of the importance of booster vaccinations as a whole as a preventative public health measure in reducing the burden of COVID-19. Heterologous and homologous booster vaccines were effective in reducing the risk of medically attended COVID-19 by between 6% and 14%, depending on the primary vaccination type. When considering all COVID-19 booster vaccine platforms together, observational studies demonstrate higher VE against COVID-19-related hospitalization in individuals who received a booster compared to unboosted individuals when both groups (boosted and unboosted) were compared to unvaccinated individuals.</p><p>A test-negative case&#x02013;control study (n = 1572 cases, n = 1609 controls) reported a VE of 77% (95% CI: 71&#x02013;82%) for a primary series and booster vaccine compared to unvaccinated persons and a VE of 44% (95% CI: 31&#x02013;54%; <italic toggle="yes">p</italic> &#x0003c; 0.001) for a primary series alone compared to unvaccinated persons [<xref rid="B16-vaccines-13-00166" ref-type="bibr">16</xref>]. Other studies of the relative effectiveness estimates of the Ad26.COV2.S booster vaccine have limited precision mainly due to their small sample sizes. A test-negative study of vaccine effectiveness (VE) among individuals hospitalized in the U.S. from 25 December 2021 to 4 April 2022, the period during which the Omicron variant was the most prevalent, reported a relative effectiveness estimate of 49% (95% CI: &#x02212;9&#x02013;76%) for the Ad26.COV2.S booster vaccine compared to an Ad26.COV2.S primary series vaccine alone [<xref rid="B17-vaccines-13-00166" ref-type="bibr">17</xref>]. The sample size for the number of individuals with an Ad26.COV2.S primary series was 96, and the sample size for the number of individuals with an Ad26.COV2.S primary series plus a booster was 65. A different U.S.-based test-negative VE study, which compared both individuals boosted with an Ad26.COV2.S vaccine and individuals with a primary Ad26.COV2.S vaccine alone to individuals with no COVID-19 vaccine, did not report an increased VE (Ad26.COV2.S boosted: VE 35% (95% CI: &#x02212;54&#x02013;73%); Ad26.COV2.S primary series only: VE 32% (95% CI: 1&#x02013;54%; <italic toggle="yes">p</italic> = 0.79)) [<xref rid="B16-vaccines-13-00166" ref-type="bibr">16</xref>]. The sample size of individuals who received an Ad26.COV2.S booster dose was 25, making it difficult to derive meaningful inferences. A strength of the current study is the relatively larger sample size for both heterologous and homologous COVID-19 booster groups.</p><p>This study has several limitations. COVID-19 vaccination status may be under-ascertained. The data source leveraged for this study captures real-world vaccine status in the study sample using CPT or NDC codes in procedure and/or pharmacy claims, respectively. Not all providers in the U.S. submit for reimbursement for vaccine administration due to no-cost government vaccination programs.</p><p>Similarly, COVID-19 infection status may be under-ascertained due to the impact of at-home testing. We caution that the results of this study focus on more severe COVID-19 outcomes of interest rather than on non-serious outcomes; as a result, the incidence rates of the outcomes observed in this study may be lower than those observed in general COVID-19-related infections that may be captured in a clinical trial setting. However, the use of different data sources to ascertain outcomes (e.g., evidence of diagnoses, procedures, and lab test results) allows for improved capture of COVID-19 events.</p><p>There may be unmeasured or residual confounding in this observational study. Unlike in a clinical trial, exposure assignment was not randomized, resulting in the possibility of unmeasured confounding of an unknown magnitude of the exposure&#x02013;outcome association. Disruptions to the healthcare system as a result of the COVID-19 pandemic, along with the accompanying influence of COVID-19 on disease outcomes, precluded the use of methods such as negative controls to assess for such potential confounding. However, at baseline, the exposure groups were overall similar, with two or fewer measured characteristics imbalanced prior to PS matching. To mitigate bias and facilitate confounding control, this study measured a large set of demographic, clinical, and utility-related characteristics. PS matching and doubly robust model specification were then applied to this set of characteristics, mimicking a clinical trial&#x02019;s randomization and minimizing the chance of spurious effect estimates due to potential confounders.</p><p>This study used data from a large and generalizable U.S. population-based dataset. Real-world data are generated during routine clinical care and are representative of the underlying populations. The source data include 16 individual-linked data sources of medical and pharmacy claims data, hospital transactional records for inpatient and outpatient hospital encounters (also known as chargemaster data), and laboratory data, and they include populations covered by commercial insurance, Medicare Advantage, and Medicaid. The results of this study may be generalizable to the broader U.S. adult population.</p></sec><sec sec-type="conclusions" id="sec5-vaccines-13-00166"><title>5. Conclusions</title><p>This population-based observational cohort study from clinical practice in the U.S. demonstrates the effectiveness of an Ad26.COV2.S booster vaccination for at least 12 months. In the U.S., individuals who were boosted with Ad26.COV2.S were at a lower risk of COVID-19 hospitalization and medically attended COVID-19 than unboosted individuals. This study adds to the volume of evidence that demonstrates the added benefit of COVID-19 vaccine booster doses that is critical to guiding the development of sound public health policy.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vaccines-13-00166"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vaccines13020166/s1">https://www.mdpi.com/article/10.3390/vaccines13020166/s1</uri>, Supplemental Table S1. Variable definitions. Supplemental Table S2a: Baseline characteristics, pre-PS matching, for mRNA + Ad26.COV2.S vs. primary series. Supplemental Table S2b: Baseline characteristics, pre-PS matching, for Ad26.COV2.S + Ad26.COV2.S vs. primary series. Supplemental Table S3a. Baseline characteristics, pre-PS matching, for mRNA + Ad26.COV2.S vs. primary series among patients in the California state registry. Supplemental Table S3b. Baseline characteristics, pre-PS matching, for Ad26.COV2.S + Ad26.COV2.S vs. primary series among patients in the California state registry. Supplemental Table S4a. Baseline characteristics, post-PS matching, for mRNA + Ad26.COV2.S vs. primary series among patients in the California state registry. Supplemental Table S4b. Baseline characteristics, post-PS matching, for Ad26.COV2.S + Ad26.COV2.S vs. primary series among patients in the California state registry. Supplemental Table S5. Adjusted hazard ratios for COVID-19-related hospitalization and medically attended COVID-19 among patients in the California state registry. Figure S1. Study population flow diagram, mRNA + Ad26.COV2.S vs. mRNA + no boost. Figure S2. Study population flow diagram, mRNA + Ad26.COV2.S vs. Ad26.COV2.S + no boost. Figure S3. Study population flow diagram, Ad26.COV2.S + Ad26.COV2.S vs. mRNA + no boost. Figure S4. Study population flow diagram, Ad26.COV2.S + Ad26.COV2.S vs. Ad26.COV2.S + no boost.</p><supplementary-material id="vaccines-13-00166-s001" position="float" content-type="local-data"><media xlink:href="vaccines-13-00166-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, A.M., L.R., L.S.Y., P.S., R.A.H., M.N., and D.R.; methodology, A.M., L.R., L.S.Y., P.S., R.A.H., M.N., and D.R.; formal analysis, L.S.Y., A.M., P.S., M.I., and T.Z.; investigation, L.S.Y., L.R., A.M., M.I., and T.Z.; writing&#x02014;original draft, L.S.Y., A.M., and M.I.; writing&#x02014;review and editing, A.M., M.N., R.A.H., and D.R.; supervision, A.M. and M.N. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was granted exemption from IRB review by the Sterling IRB pursuant to the terms of the U.S. Health and Human Services&#x02019; Policy for the Protection of Human Research Subjects at 45 C.F.R. &#x000a7;46.104(d). The IRB determined that a Category 4 Exemption (DHHS) was applicable to the study.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Restrictions apply to the availability of these data. Data were obtained from HealthVerity and are available from the authors with the permission of HealthVerity.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>A.M., L.S.Y., L.R., P.S., M.I., and T.Z. were employees and/or held stock options or equity in Aetion, a software-enabled healthcare analytics company, at the time this paper was written. M.N., R.A.H., and D.R. are employees of Johnson &#x00026; Johnson Innovative Medicine, the manufacturer of the studied vaccine Ad26.COV2.S, and hold stock options or equity in the company.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-13-00166"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Steele</surname><given-names>M.K.</given-names></name>
<name><surname>Couture</surname><given-names>A.</given-names></name>
<name><surname>Reed</surname><given-names>C.</given-names></name>
<name><surname>Iuliano</surname><given-names>D.</given-names></name>
<name><surname>Whitaker</surname><given-names>M.</given-names></name>
<name><surname>Fast</surname><given-names>H.</given-names></name>
<name><surname>Hall</surname><given-names>A.J.</given-names></name>
<name><surname>MacNeil</surname><given-names>A.</given-names></name>
<name><surname>Cadwell</surname><given-names>B.</given-names></name>
<name><surname>Marks</surname><given-names>K.J.</given-names></name>
<etal/>
</person-group><article-title>Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented Among Vaccinated Persons in the US, December 2020 to September 2021</article-title><source>JAMA Netw. Open</source><year>2022</year><volume>5</volume><fpage>e2220385</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.20385</pub-id><pub-id pub-id-type="pmid">35793085</pub-id>
</element-citation></ref><ref id="B2-vaccines-13-00166"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamana</surname><given-names>T.K.</given-names></name>
<name><surname>Galanti</surname><given-names>M.</given-names></name>
<name><surname>Pei</surname><given-names>S.</given-names></name>
<name><surname>Di Fusco</surname><given-names>M.</given-names></name>
<name><surname>Angulo</surname><given-names>F.J.</given-names></name>
<name><surname>Moran</surname><given-names>M.M.</given-names></name>
<name><surname>Khan</surname><given-names>F.</given-names></name>
<name><surname>Swerdlow</surname><given-names>D.L.</given-names></name>
<name><surname>Shaman</surname><given-names>J.</given-names></name>
</person-group><article-title>The Impact of COVID-19 Vaccination in the US: Averted Burden of SARS-CoV-2-Related Cases, Hospitalizations and Deaths</article-title><source>PLoS ONE</source><year>2023</year><volume>18</volume><elocation-id>e0275699</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0275699</pub-id><pub-id pub-id-type="pmid">37098043</pub-id>
</element-citation></ref><ref id="B3-vaccines-13-00166"><label>3.</label><element-citation publication-type="gov"><article-title>Authorizations of Emergency Use of Certain Biological Products During the COVID-19 Pandemic Availability</article-title><comment>Available online: <ext-link xlink:href="https://www.federalregister.gov/documents/2021/05/27/2021-11234/authorizations-of-emergency-use-of-certain-biological-products-during-the-covid-19-pandemic" ext-link-type="uri">https://www.federalregister.gov/documents/2021/05/27/2021-11234/authorizations-of-emergency-use-of-certain-biological-products-during-the-covid-19-pandemic</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-02-15">(accessed on 15 February 2024)</date-in-citation></element-citation></ref><ref id="B4-vaccines-13-00166"><label>4.</label><element-citation publication-type="webpage"><article-title>Vaccine Monitor: Eagerness to Get Vaccinated Begins to Level Off as Most People Who Want a Vaccine Have Gotten One, but Republicans Show Biggest Shift Toward Vaccination. KFF</article-title><year>2021</year><comment>Available online: <ext-link xlink:href="https://www.kff.org/coronavirus-covid-19/press-release/vaccine-monitor-eagerness-to-get-vaccinated-begins-to-level-off-as-most-people-who-want-a-vaccine-have-gotten-one-but-republicans-show-biggest-shift-toward-vaccination/" ext-link-type="uri">https://www.kff.org/coronavirus-covid-19/press-release/vaccine-monitor-eagerness-to-get-vaccinated-begins-to-level-off-as-most-people-who-want-a-vaccine-have-gotten-one-but-republicans-show-biggest-shift-toward-vaccination/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-03">(accessed on 3 January 2025)</date-in-citation></element-citation></ref><ref id="B5-vaccines-13-00166"><label>5.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>CDC</collab>
</person-group><article-title>COVID Data Tracker</article-title><comment>Available online: <ext-link xlink:href="https://covid.cdc.gov/covid-data-tracker" ext-link-type="uri">https://covid.cdc.gov/covid-data-tracker</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-11-08">(accessed on 8 November 2021)</date-in-citation></element-citation></ref><ref id="B6-vaccines-13-00166"><label>6.</label><element-citation publication-type="gov"><article-title>Coronavirus (COVID-19) Update: FDA Expands Eligibility for COVID-19 Vaccine Boosters</article-title><comment>Available online: <ext-link xlink:href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters" ext-link-type="uri">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-27">(accessed on 27 January 2025)</date-in-citation></element-citation></ref><ref id="B7-vaccines-13-00166"><label>7.</label><element-citation publication-type="gov"><article-title>Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals</article-title><comment>Available online: <ext-link xlink:href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised" ext-link-type="uri">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-02-15">(accessed on 15 February 2024)</date-in-citation></element-citation></ref><ref id="B8-vaccines-13-00166"><label>8.</label><element-citation publication-type="gov"><article-title>Coronavirus (COVID-19) Update: 29 October 2021</article-title><comment>Available online: <ext-link xlink:href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-october-29-2021" ext-link-type="uri">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-october-29-2021</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-02-15">(accessed on 15 February 2024)</date-in-citation></element-citation></ref><ref id="B9-vaccines-13-00166"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Borobia</surname><given-names>A.M.</given-names></name>
<name><surname>Carcas</surname><given-names>A.J.</given-names></name>
<name><surname>P&#x000e9;rez-Olmeda</surname><given-names>M.</given-names></name>
<name><surname>Casta&#x000f1;o</surname><given-names>L.</given-names></name>
<name><surname>Bertran</surname><given-names>M.J.</given-names></name>
<name><surname>Garc&#x000ed;a-P&#x000e9;rez</surname><given-names>J.</given-names></name>
<name><surname>Campins</surname><given-names>M.</given-names></name>
<name><surname>Portol&#x000e9;s</surname><given-names>A.</given-names></name>
<name><surname>Gonz&#x000e1;lez-P&#x000e9;rez</surname><given-names>M.</given-names></name>
<name><surname>Morales</surname><given-names>M.T.G.</given-names></name>
<etal/>
</person-group><article-title>Immunogenicity and Reactogenicity of BNT162b2 Booster in ChAdOx1-S-Primed Participants (CombiVacS): A Multicentre, Open-Label, Randomised, Controlled, Phase 2 Trial</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>121</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)01420-3</pub-id><pub-id pub-id-type="pmid">34181880</pub-id>
</element-citation></ref><ref id="B10-vaccines-13-00166"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khoury</surname><given-names>D.S.</given-names></name>
<name><surname>Cromer</surname><given-names>D.</given-names></name>
<name><surname>Reynaldi</surname><given-names>A.</given-names></name>
<name><surname>Schlub</surname><given-names>T.E.</given-names></name>
<name><surname>Wheatley</surname><given-names>A.K.</given-names></name>
<name><surname>Juno</surname><given-names>J.A.</given-names></name>
<name><surname>Subbarao</surname><given-names>K.</given-names></name>
<name><surname>Kent</surname><given-names>S.J.</given-names></name>
<name><surname>Triccas</surname><given-names>J.A.</given-names></name>
<name><surname>Davenport</surname><given-names>M.P.</given-names></name>
</person-group><article-title>Neutralizing Antibody Levels Are Highly Predictive of Immune Protection from Symptomatic SARS-CoV-2 Infection</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>1205</fpage><lpage>1211</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01377-8</pub-id><pub-id pub-id-type="pmid">34002089</pub-id>
</element-citation></ref><ref id="B11-vaccines-13-00166"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hardt</surname><given-names>K.</given-names></name>
<name><surname>Vandebosch</surname><given-names>A.</given-names></name>
<name><surname>Sadoff</surname><given-names>J.</given-names></name>
<name><surname>Le Gars</surname><given-names>M.</given-names></name>
<name><surname>Truyers</surname><given-names>C.</given-names></name>
<name><surname>Lowson</surname><given-names>D.</given-names></name>
<name><surname>Van Dromme</surname><given-names>I.</given-names></name>
<name><surname>Vingerhoets</surname><given-names>J.</given-names></name>
<name><surname>Kamphuis</surname><given-names>T.</given-names></name>
<name><surname>Scheper</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Efficacy, Safety, and Immunogenicity of a Booster Regimen of Ad26.COV2.S Vaccine against COVID-19 (ENSEMBLE2): Results of a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial</article-title><source>Lancet Infect. Dis.</source><year>2022</year><volume>22</volume><fpage>1703</fpage><lpage>1715</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00506-0</pub-id><pub-id pub-id-type="pmid">36113538</pub-id>
</element-citation></ref><ref id="B12-vaccines-13-00166"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Atmar</surname><given-names>R.L.</given-names></name>
<name><surname>Lyke</surname><given-names>K.E.</given-names></name>
<name><surname>Deming</surname><given-names>M.E.</given-names></name>
<name><surname>Jackson</surname><given-names>L.A.</given-names></name>
<name><surname>Branche</surname><given-names>A.R.</given-names></name>
<name><surname>El Sahly</surname><given-names>H.M.</given-names></name>
<name><surname>Rostad</surname><given-names>C.A.</given-names></name>
<name><surname>Martin</surname><given-names>J.M.</given-names></name>
<name><surname>Johnston</surname><given-names>C.</given-names></name>
<name><surname>Rupp</surname><given-names>R.E.</given-names></name>
<etal/>
</person-group><article-title>Homologous and Heterologous COVID-19 Booster Vaccinations</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>386</volume><fpage>1046</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2116414</pub-id><pub-id pub-id-type="pmid">35081293</pub-id>
</element-citation></ref><ref id="B13-vaccines-13-00166"><label>13.</label><element-citation publication-type="gov"><article-title>Vaccines and Related Biological Products Advisory Committee 14&#x02013;15 October 2021 Meeting Presentation. Presented at the Vaccines and Related Biological Products Advisory Committee Meeting</article-title><comment>Available online: <ext-link xlink:href="https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-october-14-15-2021-meeting-announcement" ext-link-type="uri">https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-october-14-15-2021-meeting-announcement</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-03">(accessed on 3 January 2025)</date-in-citation></element-citation></ref><ref id="B14-vaccines-13-00166"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hung Nguyen</surname><given-names>V.</given-names></name>
<name><surname>Boileau</surname><given-names>C.</given-names></name>
<name><surname>Bogdanov</surname><given-names>A.</given-names></name>
<name><surname>Sredl</surname><given-names>M.</given-names></name>
<name><surname>Bonafede</surname><given-names>M.</given-names></name>
<name><surname>Ducruet</surname><given-names>T.</given-names></name>
<name><surname>Chavers</surname><given-names>S.</given-names></name>
<name><surname>Rosen</surname><given-names>A.</given-names></name>
<name><surname>Martin</surname><given-names>D.</given-names></name>
<name><surname>Buck</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Relative Effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines and Homologous Boosting in Preventing COVID-19 in Adults in the US</article-title><source>Open Forum Infect. Dis.</source><year>2023</year><volume>10</volume><fpage>ofad288</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofad288</pub-id><pub-id pub-id-type="pmid">37496607</pub-id>
</element-citation></ref><ref id="B15-vaccines-13-00166"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>N.</given-names></name>
<name><surname>Joyal-Desmarais</surname><given-names>K.</given-names></name>
<name><surname>Ribeiro</surname><given-names>P.A.B.</given-names></name>
<name><surname>Vieira</surname><given-names>A.M.</given-names></name>
<name><surname>Stojanovic</surname><given-names>J.</given-names></name>
<name><surname>Sanuade</surname><given-names>C.</given-names></name>
<name><surname>Yip</surname><given-names>D.</given-names></name>
<name><surname>Bacon</surname><given-names>S.L.</given-names></name>
</person-group><article-title>Long-Term Effectiveness of COVID-19 Vaccines against Infections, Hospitalisations, and Mortality in Adults: Findings from a Rapid Living Systematic Evidence Synthesis and Meta-Analysis up to December, 2022</article-title><source>Lancet Respir. Med.</source><year>2023</year><volume>11</volume><fpage>439</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(23)00015-2</pub-id><pub-id pub-id-type="pmid">36780914</pub-id>
</element-citation></ref><ref id="B16-vaccines-13-00166"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adams</surname><given-names>K.</given-names></name>
<name><surname>Rhoads</surname><given-names>J.P.</given-names></name>
<name><surname>Surie</surname><given-names>D.</given-names></name>
<name><surname>Gaglani</surname><given-names>M.</given-names></name>
<name><surname>Ginde</surname><given-names>A.A.</given-names></name>
<name><surname>McNeal</surname><given-names>T.</given-names></name>
<name><surname>Talbot</surname><given-names>H.K.</given-names></name>
<name><surname>Casey</surname><given-names>J.D.</given-names></name>
<name><surname>Zepeski</surname><given-names>A.</given-names></name>
<name><surname>Shapiro</surname><given-names>N.I.</given-names></name>
<etal/>
</person-group><article-title>Vaccine Effectiveness of Primary Series and Booster Doses against COVID-19 Associated Hospital Admissions in the United States: Living Test Negative Design Study</article-title><source>BMJ</source><year>2022</year><volume>379</volume><fpage>e072065</fpage><pub-id pub-id-type="doi">10.1136/bmj-2022-072065</pub-id><pub-id pub-id-type="pmid">36220174</pub-id>
</element-citation></ref><ref id="B17-vaccines-13-00166"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lewis</surname><given-names>N.M.</given-names></name>
<name><surname>Murray</surname><given-names>N.</given-names></name>
<name><surname>Adams</surname><given-names>K.</given-names></name>
<name><surname>Surie</surname><given-names>D.</given-names></name>
<name><surname>Gaglani</surname><given-names>M.</given-names></name>
<name><surname>Ginde</surname><given-names>A.A.</given-names></name>
<name><surname>McNeal</surname><given-names>T.</given-names></name>
<name><surname>Ghamande</surname><given-names>S.</given-names></name>
<name><surname>Douin</surname><given-names>D.J.</given-names></name>
<name><surname>Talbot</surname><given-names>H.K.</given-names></name>
<etal/>
</person-group><article-title>Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021&#x02013;April 2022</article-title><source>Open Forum Infect. Dis.</source><year>2023</year><volume>10</volume><fpage>ofac698</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofac698</pub-id><pub-id pub-id-type="pmid">36695662</pub-id>
</element-citation></ref><ref id="B18-vaccines-13-00166"><label>18.</label><element-citation publication-type="gov"><article-title>Table HIC-4_ACS. Health Insurance Coverage Status and Type of Coverage by State&#x02014;All Persons: 2008 to 2019, September 2020</article-title><comment>Available online: <ext-link xlink:href="https://www.census.gov/library/publications/2023/demo/p60-281.html" ext-link-type="uri">https://www.census.gov/library/publications/2023/demo/p60-281.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-02">(accessed on 2 January 2025)</date-in-citation></element-citation></ref><ref id="B19-vaccines-13-00166"><label>19.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Centers for Disease Control and Prevention</collab>
</person-group><article-title>Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech, Moderna, and Janssen COVID-19 Booster Doses</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/acip/grade/covid-19-booster-doses.html#:~:text=COV2.S%20Vaccine%20(5%C3%971010%20viral%20particles%2C%20IM)%20should,%E2%89%A518%20years%20who%20completed%20a%20COVID%2D19%20vaccine" ext-link-type="uri">https://www.cdc.gov/acip/grade/covid-19-booster-doses.html#:~:text=COV2.S%20Vaccine%20(5%C3%971010%20viral%20particles%2C%20IM)%20should,%E2%89%A518%20years%20who%20completed%20a%20COVID%2D19%20vaccine</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-06">(accessed on 6 December 2024)</date-in-citation></element-citation></ref><ref id="B20-vaccines-13-00166"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gagne</surname><given-names>J.J.</given-names></name>
<name><surname>Glynn</surname><given-names>R.J.</given-names></name>
<name><surname>Avorn</surname><given-names>J.</given-names></name>
<name><surname>Levin</surname><given-names>R.</given-names></name>
<name><surname>Schneeweiss</surname><given-names>S.</given-names></name>
</person-group><article-title>A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better than Existing Scores</article-title><source>J. Clin. Epidemiol.</source><year>2011</year><volume>64</volume><fpage>749</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2010.10.004</pub-id><pub-id pub-id-type="pmid">21208778</pub-id>
</element-citation></ref><ref id="B21-vaccines-13-00166"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cox</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Regression Models and Life-Tables</article-title><source>J. R. Stat. Soc. Ser. B Methodol.</source><year>1972</year><volume>34</volume><fpage>187</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1111/j.2517-6161.1972.tb00899.x</pub-id></element-citation></ref><ref id="B22-vaccines-13-00166"><label>22.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Rothman</surname><given-names>K.J.</given-names></name>
<name><surname>Lash</surname><given-names>T.L.</given-names></name>
<name><surname>VanderWeele</surname><given-names>T.J.</given-names></name>
<name><surname>Haneuse</surname><given-names>S.</given-names></name>
</person-group><source>Modern Epidemiology</source><edition>4th ed.</edition><publisher-name>Wolters Kluwer</publisher-name><publisher-loc>Philadelphia, PA, USA</publisher-loc><year>2021</year><isbn>978-1-4511-9328-2</isbn></element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00166-f001"><label>Figure 1</label><caption><p>Study design diagram.</p></caption><graphic xlink:href="vaccines-13-00166-g001" position="float"/></fig><table-wrap position="float" id="vaccines-13-00166-t001"><object-id pub-id-type="pii">vaccines-13-00166-t001_Table 1</object-id><label>Table 1</label><caption><p>Exposure contrasts of interest.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Contrasts of Interest</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Exposure</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Referent</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 mRNA + 1 Ad26.COV2.S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 mRNA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 mRNA + 1 Ad26.COV2.S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 Ad26.COV2.S</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 Ad26.COV2.S + 1 Ad26.COV2.S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 mRNA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 Ad26.COV2.S + 1 Ad26.COV2.S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 Ad26.COV2.S</td></tr></tbody></table><table-wrap-foot><fn><p>&#x0201c;+&#x0201d; differentiates between the primary vaccination series and booster vaccination such that &#x0201c;2 mRNA + 1 Ad26.COV2.S&#x0201d; refers to a two-dose mRNA primary vaccination series followed by a single-dose Ad26.COV2.S booster vaccine. mRNA refers to a BNT162b2 or mRNA-1273 vaccination. The completed primary vaccination series (i.e., 2 mRNA vaccinations) must be from the same manufacturer (i.e., homologous primary vaccination). &#x0201c;Referent&#x0201d; is defined as the comparator group consisting of individuals with an mRNA primary vaccine series (two doses) alone (i.e., without evidence of a booster vaccine) and those with an Ad26.COV2.S vaccine (one dose) alone.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00166-t002"><object-id pub-id-type="pii">vaccines-13-00166-t002_Table 2</object-id><label>Table 2</label><caption><p>Baseline characteristics, post-PS matching, for mRNA + Ad26.COV2.S vs. primary series.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristic <sup>a</sup></th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">mRNA + Ad26.COV2.S vs. mRNA + No Boost</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">mRNA + Ad26.COV2.S vs. Ad26.COV2.S + No Boost</th></tr><tr><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N (%) or Mean +/&#x02212; SD Unless Otherwise Noted</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA + Ad26.COV2.S</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA + No Boost</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ASD</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA + Ad26.COV2.S</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad26.COV2.S + No Boost</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ASD</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Number of individuals</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2969</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11,492</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2973</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11,568</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Demographics</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age, mean (SD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.89 (15.58)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.69 (15.29)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.013</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.89 (15.56)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.88 (15.40)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male sex; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1581 (53.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6253 (54.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1587 (53.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6170 (53.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U.S. region <sup>b</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;Northeast; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">474 (16.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1820 (15.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">474 (15.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1836 (15.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;Midwest; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">320 (10.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1229 (10.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">321 (10.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1242 (10.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;South; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">648 (21.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2511 (21.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">651 (21.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2537 (21.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;West; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1527 (51.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5932 (51.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1527 (51.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5953 (51.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">State <sup>c</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.053</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.042</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Index months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.018</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;October 2021; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">125 (4.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">499 (4.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">125 (4.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">509 (4.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;November 2021; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">877 (29.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3343 (29.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">876 (29.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3360 (29.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;December 2021; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1169 (39.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4502 (39.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1171 (39.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4567 (39.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;January 2022; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">403 (13.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1609 (14.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">406 (13.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1597 (13.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;February 2022 to September 2022; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">395 (13.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1539 (13.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">395 (13.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1535 (13.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Commercial Enrollment on CED; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1631 (54.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6343 (55.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1634 (55.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6338 (54.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medicare Advantage Enrollment on CED; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">203 (6.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">795 (6.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">201 (6.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">783 (6.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medicaid Enrollment on CED; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1245 (41.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4762 (41.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.010</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1247 (41.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4845 (41.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">COVID-19-related characteristics</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Receipt of any laboratory test for COVID-19; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">832 (28.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3214 (28.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">835 (28.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3294 (28.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">History of COVID-19 infection; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">269 (9.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1024 (8.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">270 (9.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1052 (9.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Month of primary vaccination; n (%) <sup>d</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;January 2021; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91 (3.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">328 (2.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.012</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91 (3.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">377 (3.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;February 2021; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">301 (10.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1150 (10.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.004</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">301 (10.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1150 (9.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;March 2021; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">392 (13.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1502 (13.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.004</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">392 (13.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1549 (13.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;April 2021; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1033 (34.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3997 (34.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1032 (34.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3949 (34.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;May 2021; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">752 (25.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2947 (25.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.007</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">755 (25.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2910 (25.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;June 2021 to July 2022; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">400 (13.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1568 (13.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">402 (13.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1633 (14.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Days since primary series (SD) <sup>a</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">245.07 (52.94)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">244.93 (54.54)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">245.02 (52.81)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">244.88 (53.81)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Comorbid conditions</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cerebrovascular disease; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">101 (3.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">385 (3.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">101 (3.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">358 (3.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.017</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chronic kidney disease (CKD); n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">122 (4.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">462 (4.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">122 (4.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">472 (4.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chronic obstructive pulmonary disease (COPD); n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">397 (13.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1544 (13.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.002</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">399 (13.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1528 (13.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cystic fibrosis; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33 (1.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">126 (1.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32 (1.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">133 (1.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypertension; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">923 (31.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3558 (31.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">922 (31.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3590 (31.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunocompromised state from organ transplant; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (0.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40 (0.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.002</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (0.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41 (0.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunocompromised state from blood transplant; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (0.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41 (0.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.013</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (0.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56 (0.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver disease; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">205 (6.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">766 (6.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.010</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">207 (7.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">808 (7.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Malignancies; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">105 (3.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">393 (3.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.006</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">105 (3.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">432 (3.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderate-to-severe asthma; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35 (1.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">142 (1.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35 (1.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">136 (1.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurologic conditions; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">950 (32.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3626 (31.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.010</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">954 (32.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3651 (31.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Obesity; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">730 (24.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2792 (24.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.007</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">730 (24.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2829 (24.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pulmonary fibrosis; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (0.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48 (0.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.002</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (0.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44 (0.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serious heart conditions; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">258 (8.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">998 (8.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">259 (8.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1003 (8.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sickle cell disease; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thalassemia; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (0.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (0.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (0.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Type 1 diabetes mellitus; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38 (1.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">156 (1.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.007</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38 (1.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">155 (1.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Type 2 diabetes mellitus; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">446 (15.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1713 (14.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">444 (14.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1714 (14.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gagne combined comorbidity score, mean (SD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.80 (1.76)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.79 (1.75)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.009</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.81 (1.76)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.79 (1.75)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Healthcare resource utilization</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recent medical claim; n (%) <sup>e</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017 (67.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7640 (66.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.031</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018 (67.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7727 (66.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.023</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recent pharmacy claim; n (%) <sup>e</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2058 (69.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7811 (68.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.029</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2061 (69.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7982 (69.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.007</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: ASD = absolute standardized difference; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; HIV = human immunodeficiency virus; ICU = intensive care unit; Ad26.COV2.S = Johnson &#x00026; Johnson; mRNA = messenger ribonucleic acid; PS = propensity score; SD = standard deviation. <sup>a</sup> Characteristics reported for population matched by propensity scores. Unless otherwise noted, demographic variables were assessed at cohort entry (index), and comorbidities and clinical utilization variables were assessed during the 1 year before cohort entry. <sup>b</sup> Variables excluded from the final propensity score models for overall and all stratified results. <sup>c</sup> Individual state covariates are not shown for brevity. <sup>d</sup> Month of primary vaccination refers to the month of completion of either a single-dose Ad26.COV2.S primary vaccine series occurring at any time between 1 January 2021 and 6 July 2022 (61 days prior to the last possible index date) or a homologous two-dose mRNA primary vaccine series occurring between 1 January 2021 and 6 April 2022 (152 days prior to the last possible index date). June 2021&#x02013;July 2022 are presented as aggregated frequencies; ASDs are not reported. <sup>e</sup> Recent medical and pharmacy claims were defined as claims beginning during the 60 days before cohort entry.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00166-t003"><object-id pub-id-type="pii">vaccines-13-00166-t003_Table 3</object-id><label>Table 3</label><caption><p>Baseline characteristics, post-PS matching, for Ad26.COV2.S + Ad26.COV2.S vs. primary series.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristic <sup>a</sup></th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Ad26.COV2.S + Ad26.COV2.S vs. mRNA + No Boost</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Ad26.COV2.S + Ad26.COV2.S vs. Ad26.COV2.S + No Boost</th></tr><tr><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N (%) or Mean +/&#x02212; SD Unless Otherwise Noted</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad26.COV2.S + Ad26.COV2.S</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA + No Boost</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ASD</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad26.COV2.S + Ad26.COV2.S</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad26.COV2.S + No Boost</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ASD</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Number of individuals</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74,628</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">289,215</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43,072</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">166,907</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Demographics</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age, mean (SD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.19 (14.93)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.14 (14.69)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49.08 (15.46)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49.04 (15.03)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male sex; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36,904 (49.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">143,114 (49.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21,373 (49.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">82,901 (49.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U.S. region <sup>b</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;Northeast; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14,866 (19.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56,825 (19.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8838 (20.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33,913 (20.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;Midwest; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12,125 (16.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46,705 (16.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7593 (17.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29,046 (17.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;South; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15,255 (20.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58,243 (20.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9536 (22.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36,558 (21.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;West; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32,382 (43.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">127,442 (44.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17,105 (39.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67,390 (40.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">State <sup>c</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.022</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Index months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.008</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;October 2021; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5981 (8.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22,810 (7.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5593 (13.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21,758 (13.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;November 2021; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25,936 (34.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100,700 (34.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17,467 (40.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68,010 (40.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;December 2021; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22,071 (29.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86,077 (29.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,297 (23.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39,928 (23.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;January 2022; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12,009 (16.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46,440 (16.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5457 (12.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20,981 (12.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;February 2022 to September 2022; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8631 (11.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33,188 (11.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4258 (9.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16,230 (9.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Commercial Enrollment on CED; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38,657 (51.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">151,204 (52.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.010</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22,411 (52.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87,390 (52.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medicare Advantage Enrollment on CED; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6748 (9.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25,518 (8.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.008</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3593 (8.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13,676 (8.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medicaid Enrollment on CED; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30,444 (40.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">117,236 (40.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17,825 (41.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68,698 (41.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">COVID-19-related characteristics</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Receipt of any laboratory test for COVID-19; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16,466 (22.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">63,213 (21.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9619 (22.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36,575 (21.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.010</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">History of COVID-19 infection; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6371 (8.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24,115 (8.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.007</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3724 (8.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14,086 (8.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Month of primary vaccination; n (%) <sup>d</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;January 2021; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;February 2021; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;March 2021; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20,103 (26.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77,512 (26.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,407 (24.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40,411 (24.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;April 2021; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29,642 (39.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">116,132 (40.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.009</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15,881 (36.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62,149 (37.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;May 2021; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11,169 (15.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42,657 (14.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.006</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6933 (16.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26,638 (16.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;June 2021 to July 2022; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13,713 (18.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52,910 (18.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9851 (22.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37,709 (22.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Days since primary series (SD) <sup>a</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">230.89 (52.73)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">228.19 (52.57)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.051</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">215.99 (51.55)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">216.08 (51.60)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Comorbid conditions</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cerebrovascular disease; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2599 (3.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9786 (3.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1438 (3.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5475 (3.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chronic kidney disease (CKD); n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3824 (5.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14,510 (5.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1997 (4.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7642 (4.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chronic obstructive pulmonary disease (COPD); n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9521 (12.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36,249 (12.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.007</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5460 (12.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20,861 (12.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cystic fibrosis; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">541 (0.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2110 (0.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">313 (0.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1189 (0.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypertension; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27,665 (37.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">105,077 (36.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14,901 (34.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56,873 (34.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunocompromised state from organ transplant; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">387 (0.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1504 (0.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">226 (0.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">859 (0.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunocompromised state from blood transplant; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">398 (0.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1494 (0.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.002</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">211 (0.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">809 (0.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver disease; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4850 (6.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18,217 (6.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.008</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2713 (6.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,232 (6.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Malignancies; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3016 (4.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11,496 (4.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1640 (3.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6230 (3.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderate-to-severe asthma; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1013 (1.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3851 (1.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.002</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">605 (1.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2351 (1.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurologic conditions; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23,443 (31.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88,880 (30.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13,303 (30.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50,507 (30.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Obesity; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19,819 (26.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75,199 (26.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.013</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11,117 (25.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42,301 (25.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pulmonary fibrosis; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">442 (0.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1663 (0.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.002</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">246 (0.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">946 (0.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serious heart conditions; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6927 (9.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26,164 (9.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.008</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3697 (8.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14,064 (8.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sickle cell disease; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67 (0.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">253 (0.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43 (0.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">168 (0.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thalassemia; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96 (0.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">357 (0.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52 (0.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">185 (0.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Type 1 diabetes mellitus; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">831 (1.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3118 (1.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">457 (1.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1740 (1.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Type 2 diabetes mellitus; n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13,604 (18.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51,170 (17.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7146 (16.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27,406 (16.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gagne combined comorbidity score, mean (SD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.69 (1.66)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.67 (1.66)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.012</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.68 (1.64)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.67 (1.64)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Healthcare resource utilization</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recent medical claim; n (%) <sup>e</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48,085 (64.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">183,968 (63.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.017</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27,622 (64.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">106,136 (63.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recent pharmacy claim; n (%) <sup>e</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53,039 (71.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">202,604 (70.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.022</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30,194 (70.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">115,927 (69.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.014</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: ASD = absolute standardized difference; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; HIV = human immunodeficiency virus; ICU = intensive care unit; Ad26.COV2.S = Johnson &#x00026; Johnson; mRNA = messenger ribonucleic acid; PS = propensity score; SD = standard deviation. <sup>a</sup> Characteristics reported for population matched by propensity scores. Unless otherwise noted, demographic variables were assessed at cohort entry (index), and comorbidities and clinical utilization variables were assessed during the 1 year before cohort entry. <sup>b</sup> Variables excluded from the final propensity score models for overall and all stratified results. <sup>c</sup> Individual state covariates are not shown for brevity. <sup>d</sup> Month of primary vaccination refers to the month of completion of either a single-dose Ad26.COV2.S primary vaccine series occurring at any time between 1 January 2021 and 6 July 2022 (61 days prior to the last possible index date) or a homologous two-dose mRNA primary vaccine series occurring between 1 January 2021 and 6 April 2022 (152 days prior to the last possible index date). June 2021&#x02013;July 2022 are presented as aggregated frequencies; ASDs are not reported. <sup>e</sup> Recent medical and pharmacy claims were defined as claims beginning during the 60 days before cohort entry.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00166-t004"><object-id pub-id-type="pii">vaccines-13-00166-t004_Table 4</object-id><label>Table 4</label><caption><p>Adjusted hazard ratios for COVID-19-related hospitalization and medically attended COVID-19.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N Events</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Person-Years</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Incidence Rate (per 1000 Person-Years)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Median Days Follow-Up [IQR]</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Fully Adjusted HR (95% CI) *</th></tr></thead><tbody><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">mRNA + Ad26.COV2.S vs. mRNA + no boost</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">COVID-19-related hospitalization</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA + Ad26.COV2.S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1867</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">272 (168, 303)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.67 (0.43, 1.06)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA + no boost (ref)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">103</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5464</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.85</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">208 (35, 295)</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Medically attended COVID-19</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA + Ad26.COV2.S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">246</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1780</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">138.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">263 (147, 301)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.84 (0.73, 0.97)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA + no boost (ref)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">876</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5133</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">170.67</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">176 (30, 289)</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">mRNA + Ad26.COV2.S vs. Ad26.COV2.S + no boost</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">COVID-19-related hospitalization</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA + Ad26.COV2.S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1868</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">272 (168, 303)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.81 (0.51, 1.27)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad26.COV2.S + no boost (ref)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5916</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.72</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">226 (56, 296)</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Medically attended COVID-19</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA + Ad26.COV2.S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">247</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1781</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">138.67</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">263 (147, 301)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.88 (0.76, 1.01)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad26.COV2.S + no boost (ref)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">899</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5568</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">161.46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">197 (45, 292)</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Ad26.COV2.S + Ad26.COV2.S vs. mRNA + no boost</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">COVID-19-related hospitalization</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad26.COV2.S + Ad26.COV2.S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">553</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51,428</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">282 (219, 312)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.82 (0.75, 0.90)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA + no boost (ref)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1916</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">137,465</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.94</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">215 (33, 294)</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Medically attended COVID-19</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad26.COV2.S + Ad26.COV2.S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6389</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48,792</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">130.94</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">273 (188, 309)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.93 (0.90, 0.96)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA + no boost (ref)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19,237</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">129,833</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">148.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">179 (30, 287)</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Ad26.COV2.S + Ad26.COV2.S vs. Ad26.COV2.S + no boost</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">COVID-19-related hospitalization</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad26.COV2.S + Ad26.COV2.S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">315</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30,038</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">292 (217, 321)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.63 (0.56, 0.72)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad26.COV2.S + no boost (ref)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1534</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88,825</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">251 (47, 308)</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Medically attended COVID-19</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad26.COV2.S + Ad26.COV2.S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3813</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28,427</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">134.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">279 (184, 318)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.94 (0.91, 0.97)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad26.COV2.S + no boost (ref)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12,425</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">83,587</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">148.65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">226 (41, 304)</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: CI = confidence interval; HR = hazard ratio; IQR = interquartile range; Ad26.COV2.S = Johnson &#x00026; Johnson; mRNA = messenger ribonucleic acid. * Fully adjusted hazard ratio refers to the hazard ratio obtained from a Cox proportional hazards model comparing study groups that were balanced using PS matching.</p></fn></table-wrap-foot></table-wrap></floats-group></article>